Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ASTM-AASTROM BIOSCIENCES: STEM CELL RESEARCH -- Ignore unavailable to you. Want to Upgrade?

To: WaveSeeker who wrote (117)	12/9/1998 8:28:00 PM
From: QuietWon	Respond to of 1084

ASTM - MUST READ - contact info & summary posts to get you up to speed (sorry if haven't included one you've preferred) these are good posts: Message 6763762 Message 6763780 Message 6763880 Message 6763956 Message 6763860 messages.yahoo.com@m2.yahoo.com Message 6763828

To: WaveSeeker who wrote (117)	12/9/1998 8:33:00 PM
From: h.l. meeks	Read Replies (1) \| Respond to of 1084

The Replicell system is designed to produce, among a broad range of other things, patient specific cells for the treatment of bone cancer, and leukemia. Anyone ever donate bone marrow? Anybody want to? I hear it's very painful. With ASTM's Replicell, a technician can produce a supply of bone marrow made in the lab. Not only revolutionary, but coming to market in Europe by the first of the year.

To: WaveSeeker who wrote (117)	12/9/1998 8:41:00 PM
From: Bo Didley	Read Replies (1) \| Respond to of 1084

More MEDIA coverage!----- here it is! wral-tv.com

To: WaveSeeker who wrote (117)	12/9/1998 8:44:00 PM
From: Haolin Ni	Read Replies (3) \| Respond to of 1084

Caution to any one intends to buy ASTM in the morning!!!!!!!!!! (from company profile) For the fiscal year ended 6/98, revenues ( of ASTM) fell 34% to $249 thousand. Net loss applicable to Common rose 47% to $21 million. Results reflect the end of research agreement with Rhone-Poulenc Rorer, $3.4 million related to the sale of preferred stock and increased development activities. ASTM has only 11.2 million cash in hand. Therefore, company has to get new money to keep its live by sell new shares or sell something else. The news about its research development will bring no profit for the company in years. Please read the charts of GERN and ENMD, which show you the risk to buy biotech company after news. The longs are plan to sell the shares and shorts want to make profit from ASTM as well. My friends and I have set the orders to short ASTM as we did in ENMD and GERN. GOOD LUCK!